Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

EU Funding For COVID-19 Drug & Diagnostic Research

Some Money Going To Work In Africa

Executive Summary

Europe’s Innovative Medicines Initiative is to get €90m in funding for programs targeting the coronavirus outbreak.

You may also be interested in...



Industry And EU Bodies Get Together On COVID-19 Threat

European industry bodies have welcomed closer cooperation with EU institutions on addressing potential drug supply problems caused by the continuing spread of the coronavirus outbreak. Fresh funding has also been allocated for research into new vaccines, treatments and diagnostic tests.

Stark COVID-19 Drug Shortages Warning From Senior EU Regulator

The deputy head of the European Medicines Agency has outlined the steps the agency is taking to assess and address the possibility of drug shortages in Europe caused by the coronavirus outbreak, as the number of cases worldwide tops the 98,000 mark. 

EU Call For Coronavirus Projects Sparks Big Pharma Interest

Europe’s Innovative Medicines Initiative is calling for R&D projects aimed at tackling the spread of COVID-19, saying that collaborative ventures have the potential to accelerate the development of therapeutics and diagnostics to tackle this and future coronavirus outbreaks.

Related Content

Topics

Latest Headlines
See All
UsernamePublicRestriction

Register

PS141739

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel